Sequential therapy with inotuzumab ozogamicin followed by CAR T-cell therapy for Philadelphia chromosome-negative acute lymphoblastic leukemia
-
- MIZUTANI Yo
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine
-
- KUSAKABE Shinsuke
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine
-
- FUKUSHIMA Kentaro
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine
-
- MURAKAMI Hiraku
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine
-
- HAMADA Masataka
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine
-
- HASEGAWA Chihiro
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine
-
- MIZUTA Emiko
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine
-
- YAMAGUCHI Yuta
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine
-
- NAKAI Ritsuko
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine
-
- KURASHIGE Ryumei
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine
-
- HINO Akihisa
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine
-
- UEDA Tomoaki
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine
-
- FUJITA Jiro
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine
-
- MIYAMURA Takako
- Department of Pediatrics, Osaka University Graduate School of Medicine
-
- HOSEN Naoki
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine
Bibliographic Information
- Other Title
-
- Philadelphia染色体陰性急性リンパ芽球性白血病の晩期再発に対するinotuzumab ozogamicinおよびCAR-Tのsequential療法
- Philadelphia センショクタイ インセイ キュウセイ リンパ ガキュウセイ ハッケツビョウ ノ バンキ サイハツ ニ タイスル inotuzumab ozogamicin オヨビ CAR-T ノ sequential リョウホウ
Search this article
Description
<p>A 25-year-old woman with a history of B-cell acute lymphoblastic leukemia over ten years ago was referred to our hospital with a chief complaint of leukoblastosis. She was participating in a JPLSG (Japanese Pediatric Leukemia/Lymphoma Study Group) clinical study at that time. We diagnosed ALL relapse by multi-color flow cytometric analysis of bone marrow samples at admission, with reference to previous JPLSG data. Because her leukemic cells were resistant to conventional cytotoxic agents, she proceeded to lymphocyte apheresis for chimeric antigen receptor T-cell (CAR-T, Tisagenlecleucel [Tisa-cel]). She received two cycles of inotuzumab ozogamicin as a bridging therapy to Tisa-cel, resulting in a hematological complete remission (minimal residual disease measured by polymerase chain reaction [PCR-MRD] was positive at 1.0×10−4). She was finally administered Tisa-cel and achieved MRD negativity. She is currently in complete remission with careful MRD monitoring. This strategy of sequential bi-targeted therapy combining antibody conjugates and CAR-T cells provides tumor control in deeper remission and minimal damage to organ function through reduced use of cytotoxic anti-tumor agents. Therefore, we believe that this therapeutic strategy is an effective and rational treatment for adolescent and young adult ALL patients.</p>
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 65 (2), 78-83, 2024
The Japanese Society of Hematology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390580859413172480
-
- NII Book ID
- AN00252940
-
- ISSN
- 18820824
- 04851439
-
- NDL BIB ID
- 033373001
-
- PubMed
- 38448002
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- PubMed
-
- Abstract License Flag
- Disallowed